Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine. These drugs are called atypical drugs and exert their action in part by occupying receptors for serotonin, particularly the 5HT2A receptor subtype. This receptor may also interfere with glucose metabolism and insulin action. The purpose of this study is to compare an atypical antipsychotic drugs, olanzapine, which acts by occupying the 5HT2A receptor, to another antipsychotic drug, amisulpride, which mainly acts through the dopamine pathway. Healthy volunteers are recruited and asked to take a single dose of each drug and of placebo on separate days. Then, a combined glucose clamp study will be performed in order to test the effects of these drugs on insulin sensitivity and insulin secretion.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Central Institute of Mental Health, Mannheim
• Collaborator: Sanofi
• Treatments: Amisulpride; Antipsychotic Agents; Insulin; Insulin, Globin Zinc; Olanzapine; Sulpiride; Sultopride

Criteria

Inclusion Criteria:

• healthy male volunteers

• written informed consent

Exclusion Criteria:

• BMI > 30 kg/m²

• Diabetes mellitus

• Hypertension

• Treatment with drugs interfering with lipid or glucose metabolism (e.g. statins, oral antidiabetic drugs, glucocorticoids)

• History of seizures